A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome

被引:20
|
作者
Royston, Patrick [1 ]
Parmar, Mahesh K. B. [1 ]
机构
[1] UCL, Inst Clin Trials & Methodol, MRC Clin Trials Unit, 90 High Holborn, London WC1V 6LJ, England
基金
英国医学研究理事会;
关键词
Randomized controlled trials; Time-to-event outcome; Logrank test; Hazard ratio; Non-proportional hazards; Versatile test; Power; Simulation; Robustness; SAMPLE-SIZE ANALYSIS; PARMAR COMBINED TEST; LOG-RANK; CLINICAL-TRIALS; VERSATILE TESTS; SURVIVAL; HAZARDS;
D O I
10.1186/s13063-020-4153-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The logrank test is routinely applied to design and analyse randomized controlled trials (RCTs) with time-to-event outcomes. Sample size and power calculations assume the treatment effect follows proportional hazards (PH). If the PH assumption is false, power is reduced and interpretation of the hazard ratio (HR) as the estimated treatment effect is compromised. Using statistical simulation, we investigated the type 1 error and power of the logrank (LR)test and eight alternatives. We aimed to identify test(s) that improve power with three types of non-proportional hazards (non-PH): early, late or near-PH treatment effects. Methods We investigated weighted logrank tests (early, LRE; late, LRL), the supremum logrank test (SupLR) and composite tests (joint, J; combined, C; weighted combined, WC; versatile and modified versatile weighted logrank, VWLR, VWLR2) with two or more components. Weighted logrank tests are intended to be sensitive to particular non-PH patterns. Composite tests attempt to improve power across a wider range of non-PH patterns. Using extensive simulations based on real trials, we studied test size and power under PH and under simple departures from PH comprising pointwise constant HRs with a single change point at various follow-up times. We systematically investigated the influence of high or low control-arm event rates on power. Results With no preconceived type of treatment effect, the preferred test is VWLR2. Expecting an early effect, tests with acceptable power are SupLR, C, VWLR2, J, LRE and WC. Expecting a late effect, acceptable tests are LRL, VWLR, VWLR2, WC and J. Under near-PH, acceptable tests are LR, LRE, VWLR, C, VWLR2 and SupLR. Type 1 error was well controlled for all tests, showing only minor deviations from the nominal 5%. The location of the HR change point relative to the cumulative proportion of control-arm events considerably affected power. Conclusions Assuming ignorance of the likely treatment effect, the best choice is VWLR2. Several non-standard tests performed well when the correct type of treatment effect was assumed. A low control-arm event rate reduced the power of weighted logrank tests targeting early effects. Test size was generally well controlled. Further investigation of test characteristics with different types of non-proportional hazards of the treatment effect is warranted.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Competing time-to-event endpoints in cardiology trials: A simulation study to illustrate the importance of an adequate statistical analysis
    Rauch, Geraldine
    Kieser, Meinhard
    Ulrich, Sandra
    Doherty, Patrick
    Rauch, Bernhard
    Schneider, Steffen
    Riemer, Thomas
    Senges, Jochen
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2014, 21 (01) : 74 - 80
  • [32] Estimating the Treatment Effect in a Subgroup Defined by an Early Post-Baseline Biomarker Measurement in Randomized Clinical Trials With Time-To-Event Endpoint
    Bornkamp, Bjoern
    Bermann, Georgina
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (01): : 19 - 28
  • [33] Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study
    Bayar, Mohamed Amine
    Le Teuff, Gwenael
    Koenig, Franz
    Le Deley, Marie-Cecile
    Michiels, Stefan
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2020, 29 (06) : 1483 - 1498
  • [34] Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes
    Uno, Hajime
    Horiguchi, Miki
    Hassett, Michael J.
    [J]. ONCOLOGIST, 2020, 25 (02): : 91 - 93
  • [35] Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors
    Hrobjartsson, Asbjorn
    Thomsen, Ann Sofia Skou
    Emanuelsson, Frida
    Tendal, Britta
    Rasmussen, Jeppe Vejlgaard
    Hilden, Jorgen
    Boutron, Isabelle
    Ravaud, Philippe
    Brorson, Stig
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2014, 43 (03) : 937 - 948
  • [36] Use of propensity score and disease risk score for multiple treatments with time-to-event outcome: a simulation study
    Zhang, Di
    Kim, Jessica
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (06) : 1103 - 1115
  • [37] Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time-to-event endpoints
    Kormaksson, Matthias
    Lange, Markus Reiner
    Demanse, David
    Strohmaier, Susanne
    Duan, Jiawei
    Xie, Qing
    Carbini, Mariana
    Bossen, Claudia
    Guettner, Achim
    Maniero, Antonella
    [J]. STATISTICS IN MEDICINE, 2024,
  • [38] Calculating the power of a planned individual participant data meta-analysis of randomised trials to examine a treatment-covariate interaction with a time-to-event outcome
    Riley, Richard D.
    Collins, Gary S.
    Hattle, Miriam
    Whittle, Rebecca
    Ensor, Joie
    [J]. RESEARCH SYNTHESIS METHODS, 2023, 14 (05) : 718 - 730
  • [39] Assessment and Implication of Prognostic Imbalance in Randomized Controlled Trials with a Binary Outcome - A Simulation Study
    Chu, Rong
    Walter, Stephen D.
    Guyatt, Gordon
    Devereaux, P. J.
    Walsh, Michael
    Thorlund, Kristian
    Thabane, Lehana
    [J]. PLOS ONE, 2012, 7 (05):
  • [40] The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials
    Eriksson, Goran
    Calverley, Peter M.
    Jenkins, Christine R.
    Anzueto, Antonio R.
    Make, Barry J.
    Lindberg, Magnus
    Fageras, Malin
    Postma, Dirkje S.
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 1457 - 1468